Real-world treatment practices and survival outcomes of patients with de novo metastatic nasopharyngeal carcinoma after chemoimmunotherapy.

This retrospective study evaluated real-world treatment practices and survival outcomes of 42 patients with de novo metastatic nasopharyngeal carcinoma (dnMNPC) treated with a combination of chemotherapy and PD-1 inhibitors. The observed response rate was 88.1%, with 47.6% of patients receiving additional locoregional radiotherapy. Patients with oligometastasis and undetectable EBV-DNA after chemoimmunotherapy exhibited superior progression-free and overall survival. The findings suggest that this combination therapy offers improved clinical efficacy for dnMNPC, particularly in patients with favorable prognostic factors. Limitations include the retrospective design and small sample size.